1. TE-8105 First-in-Human Study：“First-in-human study of a long-acting GLP-1 receptor agonist (TE-8105) in overweight or obese adults without Type 2 diabetes mellitus” J. Clin. Pharm. 2026, 66: e70224. (https://doi.org/10.1002/jcph.70224) (Impact Factor: 2.2, A leading international journal specializing in clinical pharmacology and drug development)
2. Multi-arm Linker Platform：“Bioinorganic site-specific conjugation of multi-arm linkers to create pharmaceuticals with targeting and effector functions” J. Chin. Chem. Soc. 2026, 05 May. (https://doi.org/10.1002/jccs.70204) (Invited Review article, Impact factor: 1.5)
3. TE-8105 Sublingual：“Optimized sublingual delivery of dual fatty acid-conjugated GLP-1 receptor agonist TE-8105 produces durable efficacy in diabetic mice” Int J Pharma. 2026, 694:126752. (https://doi.org/10.1016/j.ijpharm.2026.126752) (Impact Factor: 5.2, 3rd most cited journal in Pharmacy & Pharmacology out of 366 journals)
4. TE-8105：“2FA-platform generates dual fatty acid-conjugated GLP‑1 receptor agonist TE-8105 with enhanced diabetes, obesity, and NASH efficacy compared to semaglutide” J. Med. Chem. 2025, 68, 6178-6192. (https://doi.org/10.1021/acs.jmedchem.4c02153) (Impact Factor: 6.8, 3rd out of 72 journals in the Medicinal Chemistry category)